



Amendments to the Claims

1. (Previously presented) A compound of formula (1), or a salt thereof:




wherein the rings A and B are each a benzene ring, which may have 1 to 3 substituents (any adjacent two of which may be bound to one another to form a ring selected from the group consisting of



are each independently selected from the group consisting of a halogen atom, a C₁ to C₆ alkyl group, which may be substituted with a halogen atom, and a C₁ to C₆ alkoxy group;

the ring C is a 5- to 7-membered nitrogen-containing ring, which may contain, aside from the nitrogen atom, 1 to 3 heteroatoms selected from the group consisting of a nitrogen atom, a sulfur atom, and an oxygen atom;

the ring C may further contain a substituent selected from the group consisting of a C₁ to C₆ alkyl group, a hydroxyl group, a C₁ to C₆ alkoxy group, a formyl group, a C₁ to C₆ alkylcarbonyl group, a C₁ to C₆ alkoxy carbonyl group, a carbamoyl group, a mono- or di-substituted C₁ to C₆ alkylcarbamoyl group, a C₁ to C₆ alkylsulfonyl group, an amino group, a mono- or di-substituted C₁ to C₆ alkylamino group, a C₁ to C₆ alkylcarbonylamino group, a C₁ to C₆ alkoxy carbonylamino group, a C₁ to C₆ alkylsulfonylamino group, an oxo group, a 6-membered aromatic heterocyclic group, and a substituent represented by the following formula:




wherein the ring D is a 3- to 7-membered nonaromatic heterocyclic ring, which may contain, aside from the nitrogen atom, 1 to 3 heteroatoms selected from the group consisting of a nitrogen atom, a sulfur atom, and an oxygen atom and may further contain 1 or 2 oxo-substituted carbon atoms;

m is 1 or 2; and

n is 2 or 3.

2. (Previously presented) The compound according to claim 1 represented by formula (1a), or a salt thereof:




wherein the ring A is a benzene ring, which may have 1 to 3 substituents (any adjacent two of which may be bound to one another to form a ring) that are each independently selected from the group consisting of a halogen atom, a C₁ to C₆ alkyl group, which may be substituted with a halogen atom, and a C₁ to C₆ alkoxy group;

the ring C is a 5- to 7-membered nitrogen-containing ring, which may contain, aside from the nitrogen atom, 1 to 3 heteroatoms selected from the group consisting of a nitrogen atom, a sulfur atom, and an oxygen atom;

the ring C may further contain a substituent selected from the group consisting of a C₁ to C₆ alkyl group, a hydroxyl group, a C₁ to C₆ alkoxy group, a formyl group, a C₁ to C₆ alkylcarbonyl group, a C₁ to C₆ alkoxy carbonyl group, a carbamoyl group, a mono- or di-substituted C₁ to C₆ alkylcarbamoyl group, a C₁ to C₆ alkylsulfonyl group, an amino group, a mono- or di-substituted C₁ to C₆ alkylamino group, a C₁ to C₆ alkylcarbonylamino group, a C₁ to C₆ alkoxy carbonylamino group, a C₁ to C₆


alkylsulfonylamino group, an oxo group, a 6-membered aromatic heterocyclic group, and a substituent represented by the following formula:




wherein the ring D is a 3- to 7-membered nonaromatic heterocyclic ring, which may contain, aside from the nitrogen atom, 1 to 3 heteroatoms selected from the group consisting of a nitrogen atom, a sulfur atom, and an oxygen atom and may further contain 1 or 2 oxo-substituted carbon atoms; and

n is 2 or 3.

3. (Previously presented) The compound according to claim 2, or a salt thereof, wherein in the formula (1a), the ring C is represented either by the following formula:




wherein R¹ is a hydroxyl group, a C1 to C6 alkoxy group, a formyl group, a C1 to C6 alkylcarbonyl group, a C1 to C6 alkoxy carbonyl group, a carbamoyl group, a mono- or di-substituted C1 to C6 alkylcarbamoyl group, an amino group, a mono- or di-substituted C1 to C6 alkylamino group, a C1 to C6 alkylcarbonylamino group, a C1 to C6 alkoxy carbonylamino group, a C1 to C6 alkylsulfonylamino group, an oxo group, a 6-membered aromatic heterocyclic group, or a substituent represented by the following formula:




wherein the ring D is a 3- to 7-membered nonaromatic heterocyclic ring, which may contain, aside from the nitrogen atom, 1 to 3 heteroatoms selected from the group consisting of a nitrogen atom, a sulfur atom, and an oxygen atom and may further contain 1 or 2 oxo-substituted carbon atoms.

4. (Previously presented) The compound according to claim 2, or a salt thereof, wherein in the formula (1a), the ring C is represented by the following formula:




wherein X is $-\text{O}-$ or $-\text{S}(\text{O})_q-$; and q is 0, 1, or 2.

5. (Previously presented) The compound according to claim 2, or a salt thereof, wherein in the formula (1a), the ring C is a functional group represented by the following formula:




wherein R^2 is a hydrogen atom, a C_1 to C_6 alkyl group, a formyl group, a C_1 to C_6 alkylcarbonyl group, a C_1 to C_6 alkoxy carbonyl group, a carbamoyl group, a mono- or di-substituted C_1 to C_6 alkylcarbamoyl group or a C_1 to C_6 alkylsulfonyl group; and r is 1 or 2.

6. (Previously presented) The compound according to claim 2, or a salt thereof, wherein in the formula (1a), the ring C is represented by the following formula:



wherein $\text{R}^{2'}$ is an acetyl group or a methylsulfonyl group; and r is 1 or 2.

7. (Currently amended) The compound according to claim 2, or a salt thereof, wherein the ring C in the formula (1a) is represented by the following formula:



8. (Previously presented) The compound according to claim 7, or a salt thereof, wherein in the formula (1a), n is 3.

9. (Previously presented) The compound according to claim 1, wherein the compound represented by the formula (1) is 9-(4-acetylpiperazine-1-yl)-5-[3,5-bis(trifluoromethyl)benzyl]-7-(2-methylphenyl)-6-oxo-2,3,4,5-tetrahydro-6H-pyrimido[4,5-b][1,5]oxazocine.

10. (Previously presented) The compound according to claim 1, wherein the compound represented by the formula (1) is 5-[3,5-bis(trifluoromethyl)benzyl]-9-(1,1-dioxothiomorpholine-4-yl)-7-(2-methylphenyl)-6-oxo-2,3,4,5-tetrahydro-6H-pyrimido[4,5-b][1,5]oxazocine.

11. (Previously presented) The compound according to claim 1, wherein the compound represented by the formula (1) is 9-(4-acetylhomopiperazine-1-yl)-5-[3,5-bis(trifluoromethyl)benzyl]-7-(2-methylphenyl)-6-oxo-2,3,4,5-tetrahydro-6H-pyrimido[4,5-b][1,5]oxazocine.

12. (Previously presented) The compound according to claim 1, wherein the compound represented by the formula (1) is 5-[3,5-bis(trifluoromethyl)benzyl]-7-(2-methylphenyl)-9-(4-methylpiperazine-1-yl)-6-oxo-2,3,4,5-tetrahydro-6H-pyrimido[4,5-b][1,5]oxazocine.

13-14. (Cancelled)

15. (Currently amended) A method of ~~preventing or treating dysuria, including defective bladder functions such as increased urinary frequency and incontinence of urine,~~ which comprises administering a therapeutically effective amount of a compound according to claim 1, or a salt thereof to a patient in need thereof.

16-18. (Cancelled)

19. (Previously presented) A pharmaceutical composition containing a compound according to claim 1 or a salt thereof as active ingredient, and one or more pharmaceutically acceptable adjuvants.

20. (New) The method according to claim 15, wherein the dysuria is increased urinary frequency or incontinence of urine.